Welcome to our dedicated page for NewAmsterdam Pharma Company N.V news (Ticker: NAMS), a resource for investors and traders seeking the latest updates and insights on NewAmsterdam Pharma Company N.V stock.
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is a late-stage clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated LDL-C. News about NewAmsterdam frequently centers on the clinical and regulatory progress of its lead investigational CETP inhibitor, obicetrapib, and related fixed-dose combination programs with ezetimibe.
Investors and clinicians following NAMS news can expect regular updates on NewAmsterdam’s Phase 3 development program, including the PREVAIL cardiovascular outcomes trial in patients with a history of atherosclerotic cardiovascular disease, the REMBRANDT imaging trial evaluating effects on coronary plaque and inflammation, and the RUBENS trial in patients with type 2 diabetes or metabolic syndrome who require additional LDL-C lowering. Press releases also cover pooled efficacy and safety data from pivotal trials such as BROOKLYN, BROADWAY and TANDEM, as presented at major cardiology and neurology conferences and in peer-reviewed journals.
Company news additionally includes regulatory milestones, such as acceptance of marketing authorization applications for obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination by the European Medicines Agency, as well as partnership activities with the Menarini Group in Europe and collaborations like the REMBRANDT imaging partnership with Caristo Diagnostics. Corporate updates on financial results, cash position, and equity-based inducement grants under Nasdaq Listing Rule 5635(c)(4) are also disclosed through press releases and SEC filings.
By monitoring NewAmsterdam Pharma news, readers can follow the evolution of obicetrapib’s clinical evidence in LDL-C lowering, cardiovascular outcomes, coronary plaque imaging and Alzheimer’s disease biomarkers, along with the company’s progress toward potential commercialization pathways and ongoing engagement with the investment and medical communities.
NewAmsterdam Pharma (Nasdaq: NAMS) approved inducement equity awards for two non-executive hires on April 1, 2026 under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
The grants total 15,000 stock options (exercise price $32.81) and 3,200 restricted stock units, with multi-year vesting schedules tied to continued service.
NewAmsterdam Pharma (Nasdaq: NAMS) will present three digital posters at the American College of Cardiology Annual Scientific Session (ACC.26) in New Orleans, March 28-30, 2026.
The presentations cover obicetrapib kidney outcomes from BROADWAY, a pooled Phase III safety analysis, and LDL particle–CVD risk relationships, with presenters from company leadership and collaborators.
NewAmsterdam Pharma (Nasdaq: NAMS) announced inducement equity grants to two non-executive new hires under its 2024 Inducement Plan on March 2, 2026. The Compensation Committee approved options for 10,000 ordinary shares at an exercise price of $32.83 and 2,200 restricted stock units.
Options vest over four years (25% after one year, then monthly over 36 months). RSUs vest over three years in equal one-third annual installments. Awards are subject to plan and award agreement terms and Nasdaq Listing Rule 5635(c)(4).
NewAmsterdam Pharma (Nasdaq: NAMS) announced management will attend investor conferences in early March 2026, including TD Cowen (Boston, Mar 3), Leerink Partners (Miami, Mar 9) and Jefferies Biotech on the Beach (Miami Beach, Mar 10).
Presentations and a fireside chat will be webcast live via the company's investor relations site, with archived replays available after each event.
NewAmsterdam Pharma (Nasdaq: NAMS) reported full-year 2025 results and provided a corporate update highlighting regulatory, clinical and financial milestones. Key items: MAAs accepted in EMA, UK and Switzerland with decisions expected in 2H26; $728.9M cash at 12/31/2025; ongoing Phase 3 PREVAIL, REMBRANDT and RUBENS trials; RUBENS topline expected by year-end 2026; PREVAIL blinded event rate in line with BROADWAY; plan to start an Alzheimer’s trial in 2026.
Revenue fell to $22.5M (2025) from $45.6M (2024); net loss improved to $203.8M from $241.6M; SG&A rose to $106.4M.
NewAmsterdam Pharma (Nasdaq: NAMS) announced inducement grants of options covering 217,000 ordinary shares to four non-executive new hires under its 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The options carry an exercise price of $31.57 (closing price on Feb 2, 2026) and vest over four years: 25% after one year, then 36 equal monthly installments, subject to continued service and plan terms.
NewAmsterdam Pharma (Nasdaq: NAMS) said its CFO Ian Somaiya and EVP Matthew Philippe will take part in a virtual fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026 at 8:30 a.m. ET.
A live webcast will be available via the company investor relations site and an archived replay will be posted after the event.
NewAmsterdam Pharma (Nasdaq: NAMS) summarized 2025 progress and 2026 priorities for obicetrapib. Key points: EMA approval decision expected in 2H26 for obicetrapib monotherapy and obicetrapib/ezetimibe FDC; PREVAIL CVOT event rate is tracking in line with BROADWAY; RUBENS Phase 3 began enrollment in Dec 2025 with topline data expected by year-end 2026; a planned Alzheimer’s trial is set to start in 2026; year-end cash and marketable securities were approximately $729 million, which company says should fund operations through the PREVAIL readout and potential US launch.
NewAmsterdam Pharma (Nasdaq:NAMS) announced inducement stock option grants for a newly hired non-executive employee under the 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The Compensation Committee approved options covering 20,000 ordinary shares with an exercise price of $35.20 per share, equal to the closing Nasdaq price on January 2, 2026. The options vest over four years: 25% on the one-year anniversary of the vesting commencement date, then the remaining shares in 36 equal monthly installments, subject to continued service, and are governed by the 2024 Inducement Plan and an option award agreement.
NewAmsterdam Pharma (Nasdaq: NAMS) announced inducement option grants covering an aggregate of 40,000 ordinary shares to two non‑executive new hires under the 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options carry an exercise price of $39.61, equal to the closing Nasdaq price on December 1, 2025 (grant date). The shares subject to the options vest over four years: 25% on the one‑year anniversary of each vesting commencement date, then the balance in 36 equal monthly installments, subject to continued service. The options are governed by the 2024 Inducement Plan and individual option award agreements.